June 7, 2013—Bayer HealthCare Pharmaceuticals is limiting distribution of its new intrauterine device (IUD) Skyla due to high demand and productions delays, the Office of Pharmacy Affairs (OPA) has announced.
Under OPA policy, drug manufacturers can develop a limited allocation plan for 340B covered outpatient drugs when supply is inadequate to meet demand, so long as they demonstrate that 340B providers are treated the same as non-340B providers.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)